Proton pump inhibitor use and upper gastrointestinal bleeding in ICU patients receiving high-flow nasal cannula or noninvasive positive pressure ventilation: A nationwide cohort study
In a nationwide cohort study of ICU patients receiving noninvasive respiratory support, proton pump inhibitor use was not significantly associated with a reduced risk of upper gastrointestinal bleeding, suggesting that routine stress ulcer prophylaxis may not be necessary for this population.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the high-stakes environment of an intensive care unit, the human body is often pushed to its absolute limits. When a patient is critically ill, the immense physiological stress can cause the lining of the stomach and upper intestine to become thin and vulnerable, much like a wall exposed to a sudden, fierce storm. This stress can lead to the formation of ulcers and, in severe cases, dangerous bleeding. To prevent this, doctors have long used a class of powerful medications called proton pump inhibitors. These drugs act as a shield, drastically reducing the amount of acid the stomach produces, thereby giving the delicate tissue a chance to heal or stay intact. For decades, the standard practice in many hospitals has been to administer these acid-blockers to almost every patient in the intensive care unit, operating on the assumption that the risk of bleeding is high enough to warrant the treatment for everyone.
However, medical practice is constantly evolving as new evidence emerges. While these medications are effective at stopping acid, they are not without potential downsides, such as a slightly increased risk of certain infections. The big question for modern medicine has been whether this blanket approach is truly necessary for every single patient, or if it is time to be more selective. Specifically, researchers have wondered if the rule applies to patients who are breathing on their own but still need help from machines that push air into their lungs without a tube going down their throat. These patients are serious, but they are not as critically compromised as those on full mechanical ventilators. Understanding whether these patients truly need the acid-blocking shield is crucial for balancing the benefits of preventing a bleed against the risks of unnecessary medication.
A team of researchers from Japan set out to answer this question by looking at a massive amount of real-world data. They examined the medical records of nearly 9,200 adult patients admitted to intensive care units across the country over a six-year period. All of these patients were receiving noninvasive respiratory support, meaning they were using either a high-flow nasal cannula, which delivers warm, humidified air at high speeds through the nose, or noninvasive positive pressure ventilation, a mask that gently pushes air into the lungs. Crucially, none of these patients required invasive mechanical ventilation, where a tube is inserted down the throat to breathe for them. The researchers compared the outcomes of the patients who received the acid-blocking medication with those who did not receive any form of stress ulcer prophylaxis.
The study focused on the most serious type of bleeding: events severe enough to require a surgical procedure or an endoscopic intervention to stop the blood loss. When the researchers analyzed the data, they found that the rate of these severe bleeding events was remarkably low and nearly identical in both groups. About 0.9 percent of the patients who took the medication experienced a major bleed, and the exact same percentage of patients who did not take the medication suffered a similar event. In other words, the drug did not appear to provide any extra protection against severe bleeding for this specific group of patients. The analysis also showed that the medication did not improve survival rates, nor did it change the likelihood of patients being discharged alive within 90 days. Furthermore, the researchers found no significant increase in other potential harms, such as pneumonia or specific gut infections, in the group that took the medication compared to the group that did not.
The researchers did notice some interesting variations when they looked closer at specific subgroups. For instance, the data suggested that the medication might have been helpful for patients using the high-flow nasal cannula, but not for those using the mask-based ventilation. However, because the number of bleeding events in these smaller groups was very small, the researchers cautioned that these findings should be viewed as suggestions rather than definitive rules. They also noted that the overall risk of bleeding in these patients was already quite low, likely because modern intensive care has improved significantly, with earlier feeding and better overall management reducing the need for such aggressive prevention.
Ultimately, this large-scale study challenges the long-held habit of automatically prescribing acid-blocking drugs to every patient receiving noninvasive respiratory support. The evidence indicates that for the vast majority of these patients, the medication does not lower the risk of severe upper gastrointestinal bleeding. While there may be specific, rare situations where the treatment is beneficial, the findings suggest that a routine, one-size-fits-all approach is not supported by the data. This does not mean the drug is useless, but rather that its use should be reserved for patients with clear, specific risk factors, rather than given to everyone as a standard precaution. By refining who receives this treatment, doctors can avoid unnecessary medication and focus their resources on the patients who truly need them.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.